Journal of microbiology, epidemiology and immunobiologyJournal of microbiology, epidemiology and immunobiologyЖурнал микробиологии, эпидемиологии и иммунобиологии0372-93112686-7613Central Research Institute for Epidemiology1885810.36233/0372-9311-708HZKQJMORIGINAL RESEARCHESОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯResearch ArticleAntimicrobial activity of vaginal isolates of Corynebacterium amycolatum against Acinetobacter baumanniiАнтимикробная активность вагинальных изолятов Corynebacterium amycolatum в отношении Acinetobacter baumanniihttps://orcid.org/0000-0001-6231-7028GladyshevaIrina V.ГладышеваИрина Вячеславовна
Russian Federation

Cand. Sci. (Med.), senior researcher, Laboratory of microbial ecology and dysbiosis, Institute of Cellular and Intracellular Symbiosis, Ural Branch of the Russian Academy of Sciences

канд. мед. наук, в. н. с., зав. лаб. микробной экологии и дисбиозов Института клеточного и внутриклеточного симбиоза УрО РАН

gladishevaiv@yandex.ruhttps://orcid.org/0009-0007-9152-3032IvaschenkoElena V.ИващенкоЕлена Викторовна
Russian Federation

laboratory assistant-researcher, Laboratory of biomedical technologies, Institute of Cellular and Intracellular Symbiosis of the Ural branch of the Russian Academy of Sciences

лаборант-исследователь лаб. биомедицинских технологий Института клеточного и внутриклеточного симбиоза УрО РАН

ivaschenkoev@yandex.ruhttps://orcid.org/0000-0001-9644-2978FilonchikovaEkaterina S.ФилончиковаЕкатерина Сергеевна
Russian Federation

researcher, Laboratory of biomedical technologies, Institute of Cellular and Intracellular Symbiosis, Ural branch of the Russian Academy of Sciences

н. с. лаб. биомедицинских технологий Института клеточного и внутриклеточного симбиоза УрО РАН

filonchikova@inbox.ruhttps://orcid.org/0000-0002-2546-5416ShchuplovaElena A.ЩупловаЕлена Алексеевна
Russian Federation

Cand. Sci. (Biol.), senior researcher, Laboratory of microbial ecology and dysbiosis, Institute of Cellular and Intracellular Symbiosis, Ural Branch of the Russian Academy of Sciences

канд. биол. наук, с. н. с. лаб. микробной экологии и дисбиозов Института клеточного и внутриклеточного симбиоза УрО РАН

khanina83@yandex.ruhttps://orcid.org/0000-0002-0707-2977CherkasovSergey V.ЧеркасовСергей Викторович
Russian Federation

Dr. Sci. (Med.), Academician of the Russian Academy of Sciences, chief researcher, Laboratory of biomedical technologies, Institute of Cellular and Intracellular Symbiosis of the Ural Branch of the Russian Academy of Sciences

д-р мед. наук, академик РАН, г. н. с. лаб. биомедицинских технологий Института клеточного и внутриклеточного симбиоза УрО РАН

cherkasovsv@yandex.ruOrenburg Federal Research Center of the Ural Branch of the Russian Academy of SciencesФГБУН «Оренбургский федеральный исследовательский центр» УрО РАН13032026103110811909062025Copyright ©; 2026, Gladysheva I.V., Ivaschenko E.V., Filonchikova E.S., Shchuplova E.A., Cherkasov S.V.Copyright ©; 2026, Гладышева И.В., Иващенко Е.В., Филончикова Е.С., Щуплова Е.А., Черкасов С.В.2026Gladysheva I.V., Ivaschenko E.V., Filonchikova E.S., Shchuplova E.A., Cherkasov S.V.Гладышева И.В., Иващенко Е.В., Филончикова Е.С., Щуплова Е.А., Черкасов С.В.https://creativecommons.org/licenses/by/4.0https://microbiol.crie.ru/jour/article/view/18858

Introduction. Acinetobacter baumannii is a nosocomial pathogen that causes hospital-acquired infection in immunocompromised individuals and has multiple drug resistance. A. baumannii is the priority microorganism that requires new therapeutic alternatives to replace the use of antibiotics. Corynebacterium spp. may represent a promising therapeutic alternative, given the important role of individual representatives in microbiome-mediated defense against pathogens.

The aim of the work is to investigate the antimicrobial activity of cell-free supernatants (CFSs) of Corynebacterium amycolatum against clinical isolates of A. baumannii.

Materials and methods. The effect of CFSs of C. amycolatum on the growth of planktonic culture and biofilm formation of clinical isolates of A. baumannii was studied in 96-well polystyrene plates. The production of exopolysaccharides by A. baumannii after co-cultivation with CFSs of C. amycolatum was studied using the phenol-sulfuric acid method. The morphology of biofilms and the viability of test strains after preliminary treatment with CFSs of C. amycolatum were studied using scanning electron and fluorescence microscopy. The composition of the CFS of extract was studied using the GC-MS method.

Results. An inhibitory effect of CFSs of C. amycolatum on the growth of planktonic culture of all A. baumannii test strains was established. With regard to biofilm formation, the effect of CFSs was multidirectional. SEM results showed that after co-cultivation with CFSs of C. amycolatum, A. baumannii cells were scattered over the glass surface, their cell membrane was not damaged. Using fluorescence microscopy, the absence of metabolic activity of most cells, characterizing their death, was detected. GC-MS analysis revealed the presence of 4 volatile compounds including 1,4-diaza-2,5-dioxo-3 isobutylbicyclo[4.3.0]nonane, 1,2-Benzenedicarboxylic acid, dibutyl ester, ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)- and pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(phenylmethyl)-.

Conclusions. The obtained data on the antimicrobial and antibiofilm activity of C. amycolatum CFSs against A. baumannii are another argument indicating the probiotic properties of C. amycolatum. The identified chemical compounds in CFS open up the prospect for further research aimed at developing new strategies to combat infections caused by A. baumannii.

Введение. Acinetobacter baumannii является нозокомиальным патогеном, который вызывает внутрибольничную инфекцию у лиц с ослабленным иммунитетом и обладает множественной лекарственной устойчивостью. A. baumannii — лидирующий микроорганизм, который требует новых терапевтических альтернатив, заменяющих использование антибиотиков. Corynebacterium spp. могут представлять собой перспективную терапевтическую альтернативу, учитывая важную роль отдельных представителей в микробиом-опосредованной защите от патогенов.

Цель работы — исследовать антимикробную активность бесклеточных супернатантов (БКС) C. amycolatum в отношении клинических изолятов A. baumannii.

Материалы и методы. Изучение влияния БКС C. amycolatum на прирост планктонной культуры и биоплёнкообразование клинических изолятов A. baumannii проводили в 96-луночных полистироловых планшетах. Продукцию экзополисахаридов A. baumannii после сокультивирования с БКС C. amycolatum изучали фенол-сернокислым методом. Морфологию биоплёнок и жизнеспособность тест-штаммов после предварительной обработки БКС C. amycolatum исследовали с помощью сканирующей электронной и люминесцентной микроскопии. Состав экстракта БКС изучали методом газовой хроматографии, совмещённой с масс-спектрометрией (ГХ-МС).

Результаты. Установлено ингибирующее действие БКС C. amycolatum на прирост планктонной культуры всех тест-штаммов A. baumannii. В отношении биоплёнкообразования влияние БКС было разнонаправленным. Результаты сканирующей электронной микроскопии показали, что после сокультивирования с БКС С. amycolatum клетки A. baumannii располагались разрозненно по поверхности стекла, их клеточная мембрана не была повреждена. Люминесцентная микроскопия показала отсутствие метаболической активности большинства клеток, характеризующей их гибель. Анализ ГХ-МС выявил присутствие 4 летучих соединений, включая 1,4-диаза-2,5-диоксо-3 изобутилбицикло[4.3.0]нонан, 1,2-бензолдикарбоновую кислоту, эрготаман-3',6',18-трион, 12'-гидрокси-2'-метил-5'-(фенилметил)-, (5'альфа)- и пирроло[1,2-а]пиразин-1,4-дион, гексагидро-3-(фенилметил)-.

Выводы. Полученные данные об антимикробном и антибиоплёночном действии БКС C. amycolatum в отношении A. baumannii являются ещё одним аргументом, указывающим на пробиотические свойства C. amycolatum, а выявленные химические соединения в БКС открывают перспективу для дальнейших исследований, направленных на разработку новых стратегий в борьбе с инфекциями, вызванными A. baumannii.

Corynebacterium amycolatumcell-free supernatantsantimicrobial activitiesantibiofilm activitiesAcinetobacter baumanniiCorynebacterium amycolatumбесклеточные супернатантыантимикробная активностьантибиоплёночная активностьAcinetobacter baumanniiHoward A., O’Donoghue M., Feeney A., Sleator R. Acinetobacter baumannii an emerging opportunistic pathogen. Virulence. 2012;3(3):243–50. DOI: https://doi.org/10.4161/viru.19700Komolafe O. Antibiotic resistance in bacteria — an emerging public health problem. Malawi Med. J. 2003;15:63–7. DOI: https://doi.org/10.4314/mmj.v15i2.10780Wu H., Xiao Z., Lv X., et al. Drug-resistant Acinetobacter baumannii: from molecular mechanisms to potential therapeutics (review). Exp. Ther. Med. 2023;25(5):209. DOI: https://doi.org/10.3892/etm.2023.11908Yang C., Su P., Moi S., Chuang L. Biofilm formation in Acinetobacter baumannii: genotype-phenotype correlation. Molecules. 2019;24(10):1849. DOI: https://doi.org/10.3390/molecules24101849Mohamed E., Raafat M., Samir Mohamed R., et al. Acinetobacter baumannii biofilm and its potential therapeutic targets. Futur. J. Pharm. Sci. 2023;9(1):82. DOI: https://doi.org/10.1186/s43094-023-00525-w EDN: https://elibrary.ru/fsmzdtTalebi Bezmin Abadi A., Rizvanov A., Haertlé T., et al. World Health Organization report: current crisis of antibiotic resistance. BioNanoSci. 2019;9(4):778–88. DOI: https://doi.org/10.1007/s12668-019-00658-4Virgo M., Mostowy S., Ho B.T. Emerging models to study competitive interactions within bacterial communities. Trends Microbiol. 2025;33(6):688–700. DOI: https://doi.org/10.1016/j.tim.2024.12.009Dalili D., Amini M., Faramarzi M., et al. Isolation and structural characterization of Coryxin, a novel cyclic lipopeptide from Corynebacterium xerosis NS5 having emulsifying and anti-biofilm activity. Colloids Surf. B: Biointerfaces. 2015;135:425–32. DOI: https://doi.org/10.1016/J.COLSURFB.2015.07.005Hardy B., Dickey S.W., Plaut R., et al. Corynebacterium pseudodiphtheriticum exploits Staphylococcus aureus virulence components in a novel polymicrobial defense strategy. mBio. 2019;10(1):e02491–18. DOI: https://doi.org/10.1128/mBio.02491-18Huang S., Hon K., Bennett C., et al. Corynebacterium accolens inhibits Staphylococcus aureus induced mucosal barrier disruption. Front. Microbiol. 2022;13:984741. DOI: https://doi.org/10.3389/fmicb.2022.984741Gladysheva I., Cherkasov S. Antibiofilm activity of cell-free supernatants of vaginal isolates of Corynebacterium amycolatum against Pseudomonas aeruginosa and Klebsiella pneumoniae. Arch. Microbiol. 2023;205(4):158. DOI: https://doi.org/10.1007/s00203-023-03498-9Gladysheva I., Stroganova E., Chertkov K., et al. Antimicrobial activity of Corynebacterium amycolatum ICIS 53 and Corynebacterium amycolatum ICIS 82 against urogenital isolates of multidrug-resistant Staphylococcus aureus. Curr. Microbiol. 2024;81(12):426. DOI: https://doi.org/10.1007/s00284-024-03936-xScillato M., Spitale A., Mongelli G., et al. Antimicrobial properties of Lactobacillus cell-free supernatants against multidrug-resistant urogenital pathogens. Microbiologyopen. 2021;10(2):e1173. DOI: https://doi.org/10.1002/mbo3.1173Algburi A., Al-Hasani H.M., Ismael T.K., et al. Antimicrobial activity of Bacillus subtilis KATMIRA1933 and Bacillus amyloliquefaciens B-1895 against Staphylococcus aureus biofilms isolated from wound infection. Probiotics Antimicrob. Proteins. 2021;13(1):125–34. DOI: https://doi.org/10.1007/s12602-020-09673-4Chiba A., Sugimoto S., Sato F., et al. A refined technique for extraction of extracellular matrices from bacterial biofilms and its applicability. Microb. Biotechnol. 2015;8(3):392–403. DOI: https://doi.org/10.1111/1751-7915.12155/SUPPINFOContreras-Martínez O., Sierra-Quiroz D., Angulo-Ortíz A. Antibacterial and antibiofilm potential of ethanolic extracts of Duguetia vallicola (Annonaceae) against in-hospital isolates of Pseudomonas aeruginosa. Plants. 2024;13(10):1412. DOI: https://doi.org/10.3390/plants13101412Bernard K. The genus corynebacterium and other medically relevant coryneform-like bacteria. J. Clin. Microbiol. 2012;50(10): 3152–8. DOI: https://doi.org/10.1128/JCM.00796-12Palmieri B., Vadalà M., Roncati L., et al. The long-standing history of Corynebacterium parvum, immunity, and viruses. J. Med. Virol. 2020;92(11):2429–39. DOI: https://doi.org/10.1002/jmv.26100Kwaszewska A., Sobiś-Glinkowska M., Szewczyk E. Cohabitation – relationships of corynebacteria and staphylococci on human skin. Folia Microbiol. 2014;59(6):495–502. DOI: https://doi.org/10.1007/s12223-014-0326-2Szabo D., Ostorhazi E., Stercz B., et al. Specific nasopharyngeal Corynebacterium strains serve as gatekeepers against SARS-CoV-2 infection. Geroscience. 2023;45(5):2927–38. DOI: https://doi.org/10.1007/s11357-023-00850-1Ortiz Moyano R., Dentice Maidana S., Imamura Y., et al. Antagonistic effects of Corynebacterium pseudodiphtheriticum 090104 on respiratory pathogens. Microorganisms. 2024;12(7):1295. DOI: https://doi.org/10.3390/microorganisms12071295Menberu M., Cooksley C., Ramezanpour M., et al. In vitro and in vivo evaluation of probiotic properties of Corynebacterium accolens isolated from the human nasal cavity. Microbiol. Res. 2021;255:126927. DOI: https://doi.org/10.1016/j.micres.2021.126927Gladysheva I., Chertkov K., Cherkasov S., et al. Probiotic potential, safety properties, and antifungal activities of Corynebacterium amycolatum ICIS 9 and Corynebacterium amycolatum ICIS 53 strains. Probiotics Antimicrob. Proteins. 2023;15(3):588–600. DOI: https://doi.org/10.1007/s12602-021-09876-3Brugger S., Bomar L., Lemon K. Commensal-pathogen interactions along the human nasal passages. PLoS Pathog. 2016;12(7): e1005633. DOI: https://doi.org/10.1371/journal.ppat.1005633Bomar L., Brugger S., Yost B., et al. Corynebacterium accolens releases antipneumococcal free fatty acids from human nostril and skin surface triacylglycerols. MBio. 2016;7(1):e01725–15. DOI: https://doi.org/10.1128/mbio.01725-15Valcek A., Philippe C., Whiteway C., et al. Phenotypic characterization and heterogeneity among modern clinical isolates of Acinetobacter baumannii. Microbiol. Spectr. 2023;11(1):e03061–22. DOI: https://doi.org/10.1128/spectrum.03061-22Kaur N., Dey P. Bacterial exopolysaccharides as emerging bioactive macromolecules: from fundamentals to applications. Res. Microbiol. 2023;174(4):104024. DOI: https://doi.org/10.1016/j.resmic.2022.104024Rajivgandhi G., Ramachandran G., Maruthupandy M., et al. Molecular identification and structural characterization of marine endophytic actinomycetes Nocardiopsis sp. GRG 2 (KT 235641) and its antibacterial efficacy against isolated ESBL producing bacteria. Microb. Pathog. 2019;126:138–48. DOI: https://doi.org/10.1016/j.micpath.2018.10.014Vargas da Rosa B., Regina Kuhn K., Andrade Ugalde G., et al. Antioxidant compounds extracted from Diaporthe schini using supercritical CO2 plus cosolvent. Bioprocess Biosyst. Eng. 2020; 43(1):133–41. DOI: https://doi.org/10.1007/s00449-019-02211-9Zaman N.R., Chowdhury U.F., Reza R.N., et al. Plant growth promoting endophyte Burkholderia contaminans NZ antagonizes phytopathogen Macrophomina phaseolina through melanin synthesis and pyrrolnitrin inhibition. PloS One. 2021;16(9):e0257863. DOI: https://doi.org/10.1371/journal.pone.0257863Sharma M., Bharti S., Goswami A., et al. Diversity, antimicrobial, antioxidant, and anticancer activity of culturable fungal endophyte communities in Cordia dichotoma. Molecules. 2023; 28(19):6926. DOI: https://doi.org/10.3390/molecules28196926Arshad Awan Z., Shoaib A., Schenk P., et al. Antifungal potential of volatiles produced by Bacillus subtilis BS-01 against Alternaria solani in Solanum lycopersicum. Front. Plant. Sci. 2023;26:13: 1089562. DOI: https://doi.org/10.3389/fpls.2022.1089562Sannio F., Brizzi A., Del Prete R., et al. Optimization of pyrazole compounds as antibiotic adjuvants active against colistin- and carbapenem-resistant Acinetobacter baumannii. Antibiotics. 2022; 11(12):1832. DOI: https://doi.org/10.3390/ antibiotics11121832Sharma S., Raju S.,Verma S.K., et al. Pyrazoles: a master key to tackle multidrug-resistant Acinetobacter baumannii and its structure activity relationship studies. Chem. Biol. Drug Des. 2025;5(3):e70092. DOI: https://doi.org/10.1111/cbdd.70092